Find a Clinical Trial

In conjunction with our mission to advance the science and practice of clinical psychopharmacology through education and research, ASCP is committed to the support and promotion of clinical trials. We encourage practitioners and patients to investigate and participate in clinical trials when available and appropriate. To list a clinical trial on the website, please submit information to


Clinical Trial from Massachusetts General Hospital, Boston

  • NCT03553875, This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for the treatment of social impairment in youth with Non-Verbal Learning Disorder, High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will be males and females ages 8-18.

Clinical Trial from California State University, San Marcos

  •  NCT03934723, The aim of the proposed study is to compare the efficacy of 6 weeks of exercise training to reduce abdominal fat in healthy overweight/obese adults either taking or not taking antidepressant medication. Twenty-four inactive overweight/obese, but otherwise healthy, adults will complete 6 weeks of an exercise training intervention consisting of three days of aerobic exercise training per week. Participants will either not be taking antidepressant medication or will have been on their medication for at least 1 year. The primary outcome will be abdominal fat determined by waist circumference and dual x-ray absorptiometry, which is considered one of the optimal methods for assessment of abdominal fat.

Clinical Trial from Brasilia University Hospital

  • NCT03075241, Sleep disorders (SD) affects 35 to 50 percent of patients with AD. These disorders often make caring for patients at home very difficult. Zolpidem and Zoplicone are prescribed drugs for sleep disorder in AD patients.

Clinical Trial from Christoph U. Correll and Northwell University  

  • NCT01383915, The purpose of the study is to characterize the at-risk phases preceding a first episode of bipolar disorder and of schizophrenia, and to identify clinical and biological predictors of the disease development. Hypothesis a: Over 6-24 months, 25% of at-risk youth will develop the full manifestations of Bipolar Disorder (BPD) or schizophrenia. Hypothesis b: The symptoms utilized for characterizing the at-risk phase of BPD will differentiate between individuals developing BPD and schizophrenia

Clinical Trial from Yale University 

  • NCT03539900 Binge-eating disorder (BED), the most prevalent formal eating disorder, is associated strongly with obesity and bio-psychosocial impairment. Improved treatments for patients with BED are needed that can produce sustained clinical outcomes. This study aims to test the efficacy of Naltrexone/Bupropion (NB; FDA-approved anti-obesity combination medication) for the treatment of BED in patients with and without obesity. The RCT will provide new findings regarding the efficacy of NB medication for reducing binge-eating episodes among patients with BED, for reducing weight among patients with BED and obesity, and whether patients with and without obesity derive differential benefit from NB.

Clinical Trial from the University of North Carolina, Chapel Hill

  •  NCT03287778 Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia: This study will test the efficacy of pyridoxine (also known as vitamin B6) for TD. This will be an 8 week double-blind, placebo-controlled, randomized trial measuring the effect of pyridoxine 400 mg/day on the severity of involuntary muscle movements in people who meet Schooler-Kane criteria for TD..

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia 

  •  NCT03627195 A study to determine the maximum tolerated dose of an investigational drug in subjects with schizophrenia. This is a single-center, randomized, double-blind, placebo-controlled, inpatient, single ascending dose (SAD) study designed to evaluate the safety, tolerability, and PK of lurasidone injectable suspension in subjects with schizophrenia

Ion Channel Genetic Biomarkers: Diagnostic Capabilities in the Assessment of Bipolar Disorder 

  •  NCT03572426 ,Genotype 164 adults to evaluate six selected single nucleotide polymorphisms (SNPs) (rs1006737, rs10994336, rs10994133, rs2238071, rs1051375, rs1024582) for use as a genetic biomarker to differentiate between bipolar depression and unipolar depression.

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety (FiESTAA) 

  • NCT02818751 , Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents with Anxiety. To determine the effects of escitalopram on functional activation patterns during a Continuous Performance Task with Emotional and Neutral Distracters, the CPT-END.

Clinical Trials from Northwestern University Psychiatric Clinical Research Program 

  • NCT02466685, The goals of this study are to evaluate the efficacy of JNJ-18038683 in an 8 week trial to ameliorate the cognitive deficit and reduce residual depressive symptoms in 60 stable bipolar outpatients receiving treatment for depression

 Clinical Trials from Otsuka Pharmaceutical Development & Commercialization, Inc.

  • NCT03287869 A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder

Clinical Trials from Medical University of South Carolina

  • NCT03334721 Gabapentin for Bipolar & Cannabis Use Disorders

Clinical Trials from Axsome Therapeutics, Inc.

  • NCT02741791 A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder (STRIDE-1)
  • NCT03226522 Addressing Dementia Via Agitation-Centered Evaluation (ADVANCE)
  • NCT03595579  Assessing Symptomatic Clinical Episodes in Depression (ASCEND)

Clinical Trials from Azevan Pharmaceuticals

  • NCT02922166 Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

Clinical Trials from The Cleveland Clinic

  • NCT03113968 ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D)

Clinical Trials from Yale University


Clinical Trials from Weill Medical College of Cornell University

  • NCT03026127 A Novel Cognitive Reappraisal Intervention for Suicide Prevention (CRISP)

Clinical Trials from University of Maryland

  • NCT02067975 Tryptophan MRI in People With Schizophrenia and Healthy Controls
  • NCT02884908 Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD

Clinical Trials from Northwell Health

  • NCT02822092 Striatal Connectivity and Clinical Outcome in Psychosis

Clinical Trials from Duke University

  • NCT03069482 Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness

Clinical Trials from Mclean Hospital

  • NCT02188121 Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients (FITNESS)

Clinical Trials from Atlanta Center for Medical Research

  • NCT02932943 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

Clinical Trials from University of Nebraska

  • NCT02824627 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders
Clinical Trials from New York State Psychiatric Institute
  • NCT01931202 Mechanisms of Antidepressant Non-Response in Late-Life Depression
  • NCT03169816 Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
  • NCT02557945 Gabapentin in Patients at Clinical Risk for Psychosis
Clinical Trials from University of Alabama at Birmingham
  • NCT02034253 Glutamate, Brain Connectivity and Duration of Untreated Psychosis (DUP)
Clinical Trials from Florida Atlantic University
  • NCT02717130 Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

 Clinical Trials from Massachusetts General Hospital

  • NCT01246765 National Pregnancy Registry for Atypical Antipsychotics
  • NCT02505984 Preventing Postpartum Depression With Intranasal Oxytocin (IN-OXT)
Clinical Trials from Hartford University
  • NCT02120729 Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT (CYP-GUIDES)
Clinical Trials from the NIMH
  • NCT02120729 Decision Support IT System for Psychiatric Hospitalization